Evidence map›Paper›PMID 29121562›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2017

P-glycoproteins play a role in ivermectin resistance in cyathostomins.

L E Peachey, G L Pinchbeck, J B Matthews, F A Burden, A Lespine, G von Samson-Himmelstjerna, J Krücken, J E Hodgkinson

Open access · goldAbstract read
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Effect of sainfoin (Parasitology · 2022
    Article
  9. Review
  10. Article
  11. Caenorhabditis elegans in anthelmintic research - Old model, new perspectives.International journal for parasitology. Drugs and drug resistance · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway.Journal of experimental & clinical cancer research : CR · 2019
    Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

L E PeacheyInstitute of Infection and Global Health, University of Liverpool, Liverpool Science Park IC2, Brownlow Hill, Liverpool, United Kingdom. Electronic address: peachey14@hotmail.com.
G L PinchbeckInstitute of Infection and Global Health, University of Liverpool, Liverpool Science Park IC2, Brownlow Hill, Liverpool, United Kingdom.
J B MatthewsMoredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian, Scotland, United Kingdom.
F A BurdenThe Donkey Sanctuary, Sidmouth, Devon, United Kingdom.
A LespineToxalim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse, France.
G von Samson-HimmelstjernaInstitute for Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
J KrückenInstitute for Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
J E HodgkinsonInstitute of Infection and Global Health, University of Liverpool, Liverpool Science Park IC2, Brownlow Hill, Liverpool, United Kingdom.
Freie Universität Berlin · DEUniversity of Liverpool · GBMoredun Research Institute · GBSidmouth Hospital · GBToxalim Research Centre in Food Toxicology · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anthelmintic resistance is a global problem that threatens sustainable control of the equine gastrointestinal cyathostomins (Phylum Nematoda; Superfamily Strongyloidea). Of the three novel anthelmintic classes that have reached the veterinary market in the last decade, none are currently licenced in horses, hence current control regimens focus on prolonging the useful lifespan of licenced anthelmintics. This approach would be facilitated by knowledge of the resistance mechanisms to the most widely used anthelmintics, the macrocyclic lactones (ML). There are no data regarding resistance mechanisms to MLs in cyathostomins, although in other parasitic nematodes, the ABC transporters, P-glycoproteins (P-gps), have been implicated in playing an important role. Here, we tested the hypothesis that P-gps are, at least in part, responsible for reduced sensitivity to the ML ivermectin (IVM) in cyathostomins; first, by measuring transcript levels of pgp-9 in IVM resistant versus IVM sensitive third stage larvae (L3) pre-and post-IVM exposure in vitro. We then tested the effect of a range of P-gp inhibitors on the effect of IVM against the same populations of L3 using the in vitro larval development test (LDT) and larval migration inhibition test (LMIT). We demonstrated that, not only was pgp-9 transcription significantly increased in IVM resistant compared to IVM sensitive L3 after anthelmintic exposure (p < 0.001), but inhibition of P-gp activity significantly increased sensitivity of the larvae to IVM in vitro, an effect only observed in the IVM resistant larvae in the LMIT. These data strongly implicate a role for P-gps in IVM resistance in cyathostomins. Importantly, this raises the possibility that P-gp inhibitor-IVM combination treatments might be used in vivo to increase the effectiveness of IVM against cyathostomins in Equidae.

Indexed as

AnimalsAnthelminticsATP Binding Cassette Transporter, Subfamily BDrug ResistanceHorsesIvermectinLactonesLarvaLevamisoleStrongyloideaAnthelminticsATP Binding Cassette Transporter, Subfamily BIvermectinLactonesLevamisoleAnthelmintic resistanceCyathostominsIvermectinP-glycoproteins

Identifiers

PMID29121562
PMCPMC5681340
OpenAlexW2765243407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.